Eledon Pharmaceuticals is a clinical stage biotechnology company using its immunology expertise to develop therapies to protect transplanted organs and reduce the risk of organ rejection, as well as to treat autoimmune and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential.

With tegoprubart as the cornerstone of our pipeline, Eledon is poised to rapidly leverage our knowledge of anti-CD40 Ligand biology to accelerate clinical research that can bring patients a more durable and positive result after organ and cellular transplant compared to current standard of care. We are also studying use of tegoprubart in xenotransplantation procedures and advancing our work in autoimmune and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).

We are committed to making a positive difference by developing and delivering next generation therapies to manage the immune response for patients in need of potentially life-saving medicines.

Eledon has built a team of proven professionals and industry leaders with deep expertise and impressive track records in developing novel therapeutics, advancing them through the clinic and creating true value for both patients and stakeholders.


Paul Little

Chief Financial Officer

Mr. Little has served as Chief Financial Officer of Eledon since March 2021. Mr. Little has over 30 years of financial, operations, business strategy and leadership experience in global public companies. Before joining Eledon in March 2021, Mr. Little served as Chief Financial Officer of Sientra Inc., where he led finance, investor relations, information technology, and manufacturing. During his tenure at Sientra, Mr. Little successfully led multiple public financing rounds while strengthening the balance sheet and driving organizational and operational efficiencies to accelerate revenue growth while improving cash flow. Prior to Sientra, Mr. Little served as Chief Operating Officer for Candela Medical (formerly Syneron-Candela) where he led the Company’s global supply chain and service organization and helped lead the execution of the growth strategy culminating in the sale of the company. Before Candela Medical, Mr. Little served as Vice President, Finance and Commercial Operations for Allergan PLC’s Medical Aesthetics division and as a key member of the senior leadership team, helped build Allergan into the global market leader for medical aesthetics. In this role, Mr. Little built the commercial finance, commercial operations and customer operations functions from the ground up and led the financial assessment and integration of over $3B in M&A activities. He joined Allergan from ConAgra Brands, and began his career in public accounting at KPMG. Mr. Little holds a B.A. in Business Economics from the University of California, Santa Barbara.

Keith A. Katkin

Chairman of the Board of Directors

Mr. Katkin has served as Chairman of the Board of Directors of Eledon Pharmaceuticals, Inc. since the acquisition of Otic Pharma, Ltd. by Eledon Pharmaceuticals (formerly Novus Therapeutics, Inc.) in May 2017. Prior to the acquisition, Mr. Katkin served as Chairman of the Board of Directors for Otic Pharma from 2015 to 2017. Mr. Katkin served as the Principal Executive Officer and as a member of the board of directors of Urovant Sciences Ltd, a public biopharmaceutical company from September 2017 until March 2020. Mr. Katkin served as the President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from 2007 to 2016. Mr. Katkin led the growth and ultimate sale of Avanir to Otsuka Pharmaceutical Co., Ltd. for $3.5 billion. Mr. Katkin joined Avanir in 2005 as Senior Vice President of Sales and Marketing and a member of Avanir’s executive management team. Prior to joining Avanir, Mr. Katkin served as Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc., a privately-held biopharmaceutical company, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson and Johnson. Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Inc., Amgen, Inc. and Abbott Laboratories. Mr. Katkin currently serves on the Board of Directors of Syndax Pharmaceuticals, Inc., and Emergent BioSolutions, Inc. Mr. Katkin served on the board of Rigel Pharmaceuticals, Inc. until May of 2022. Mr. Katkin has an M.B.A. from the Anderson School of Business at UCLA and earned a B.S. in Business and Accounting from Indiana University. Mr. Katkin is also a certified public accountant.

June Lee, MD


Dr. Lee has served as a member of the Board of Directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) since December 2020. From February 2021 to November 2021, Dr. Lee was founder and Chief Executive Officer at Esker Therapeutics, Inc. From January 2017 until June 2020, Dr. Lee was Chief Development Officer and Chief Operating Officer of MyoKardia, Inc., a clinical stage biotechnology company with a focus on precision cardiovascular medicines. At MyoKardia she built and led a world class development organization culminating in the company’s $13.1 billion acquisition by Bristol Myers Squibb in November 2020. Prior to MyoKardia, Dr. Lee was Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator at UCSF for early-stage technologies in therapeutics, devices, diagnostics, and digital health. She is also the founding chair of the University of California Drug, Device, Discovery and Development Group. Previously, she was therapeutic area head in early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech. Dr. Lee is a member of the Board of Directors of the Council of Korean Americans, of which she previously served as Chair. She is a founding member of the Translational Research Advisory Council of South Korea’s MOGAM Research Institute, and the MTRAC for Life Sciences Innovation Hub Therapeutic/Diagnostic Oversight Committee, a unit associated with the University of Michigan Medical School. She is a Board Director for Abivax, CinCor Pharma, GenEdit and Tenaya Therapeutics, serves on Johns Hopkins University Center for Therapeutic Translation’s Advisory Board, and on the Scientific Advisory Board for Foresite Labs. Dr. Lee completed a Bachelor of Science in chemistry at the Johns Hopkins University, an M.D. at the School of Medicine at University of California, Davis, and her clinical training in internal medicine and pulmonary & critical care at UCLA and UCSF.

James Robinson


Mr. Robinson has served as a member of the Board of Directors of Eledon Pharmaceuticals, Inc. since October 2023. Mr. Robinson currently serves as Chief Executive Officer and Director of A2 Biotherapeutics, a clinical-stage cell therapy company developing cell therapies to address unmet needs in cancer. Prior to A2 Biotherapeutics, Mr. Robinson served as Chief Executive Officer and Director of Urovant Sciences from March 2020 to July 2023, guiding the company through its first product launch, and subsequent acquisition by Sumitomo Dainippon Pharma. From April 2019 to March 2020, Mr. Robinson was President and Chief Operating Officer of Paragon Biosciences. From March 2018 to April 2019, Mr. Robinson served as President and COO of Alkermes, leading operations that generated more than $1 billion in annual revenue. Prior to Alkermes, Mr. Robinson spent over 12 years at Astellas Pharma, one of the leaders in the field of solid organ transplant, where he served as President of the Americas and was responsible for $4 billion in revenue generation. Mr. Robinson currently serves on the Board of Directors of UroGen Pharma (Nasdaq: URGN) and Petauri Health. Mr. Robinson currently serves on the Board of Directors of UroGen Pharma (Nasdaq: URGN). He previously served on the Board of Directors for Neos Therapeutics and for AGTC before the company was sold to Syncona. Mr. Robinson also previously served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he served as Chairman of PhRMA’s State Committee. He earned a Bachelor of Science in marketing from DePaul University.